Results 241 to 250 of about 38,385 (346)

Insulin therapy DE‐intensificAtion with iGlarLixi: A phase 4, open‐label, parallel‐group randomised controlled trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate the efficacy and safety of transitioning from multiple daily injections (MDIs) insulin regimen to once‐daily, fixed‐ratio combination of basal insulin analog glargine 100 U/mL and a glucagon‐like peptide 1 receptor agonist lixisenatide (iGlarLixi) in people with type 2 diabetes (PwT2D). Materials and Methods Insulin therapy DE‐
Peter Novodvorský   +14 more
wiley   +1 more source

CGM‐derived average glucose is more strongly associated with microvascular complications than HbA1c in type 1 diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To compare the associations of HbA1c and continuous glucose monitoring (CGM)‐derived average glucose with microvascular complications in adults with type 1 diabetes, and to assess the clinical utility and stability of metrics capturing glycation discordance. Materials and methods Observational assessment of 9023 paired measurements of CGM
Roland H. Stimson   +7 more
wiley   +1 more source

Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Type 2 diabetes (T2D) is associated with increased dementia risk, but comparative data across newer glucose‐lowering therapies remain limited. We examined whether the initiation of GLP‐1 receptor agonists (GLP‐1 RAs) was associated with incident dementia compared with DPP4 inhibitors (DPP4is) and SGLT2 inhibitors (SGLT2is) in older adults ...
Ting Zhou   +9 more
wiley   +1 more source

Neurosteroids in pain management: A new perspective on an old player [PDF]

open access: yes, 2018
Covey, Douglas F   +3 more
core   +2 more sources

Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The risk of diabetic nephropathy among patients with type 2 diabetes (T2D) can be reduced through optimal glycaemic control. It is not known if the pharmacological properties of long‐acting insulin analogues may reduce the risk of diabetic complications compared with neutral protamine Hagedorn (NPH) insulin.
Julia Brillinger   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy